Xenon partner Neurocrine's Phase 2 trial of NBI-921352 in focal seizures fails

Xenon Pharmaceuticals Inc.

Phase 2 study of NBI-921352 in adult focal onset seizures failed to show meaningful seizure reduction.
Neurocrine will not pursue further development of NBI-921352 in focal onset seizures.
Xenon to review data for potential implications on ongoing SCN8A-developmental epileptic encephalopathy study.
Neurocrine continues pre-clinical development of dual selective Nav1.2/1.6 inhibitor under collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.